Alpha Teknova, Inc.

Health Care
Biotechnology: In Vitro & In Vivo Diagnostic Substances
www.teknova.com

Moat Score
Safety Score

Market Cap $355.72M
PE -11
Debt $14.66M
Cash $6.15M
EV $364.23M
FCF -$15.22M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$31.68M
EBIT	-$31.38M
ROE	-36%
ROA	-25%
FCF	-$15.22M
Equity	$87.27M
Growth Stability	1
PE	-11.23
PB	4.08
P/FCF	-23.38
P/S	9.79
Price/Cash	0.02
Debt/Equity	0.17
Debt/FCF	-0.96
Net Margins	-74%
Gross Margins	18%
Op. Margins	-86%
Sales Growth YoY	17%
Sales Growth QoQ	-0%
Sales CAGR	-2%
Equity CAGR	41%
Earnings Growth YoY	-25%

Earnings Growth QoQ	41%
Sales CAGR 5Y	-2%
Equity CAGR 5Y	41%
Earnings CAGR 3Y	-5%
Sales CAGR 3Y	-5%
Equity CAGR 3Y	-19%
Market Cap	$355.72M
Revenue	$36.35M
Assets	$124.10M
Total Debt	$14.66M
Cash	$6.15M
Shares Outstanding	44.52M
EV	364.23M
Moat Score	2%
Safety Score	65%
Working Capital	36.21M
Current Ratio	4.73
Gross Profit	$6.44M
Shares Growth 3y	21%
Equity Growth QoQ	11%
Equity Growth YoY	-12%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification.

SEC Filings

Direct access to Alpha Teknova, Inc. (TKNO) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Alpha Teknova, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Alpha Teknova, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Alpha Teknova, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Alpha Teknova, Inc..

Years

Calculation mode

= -$152M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$15M	-$15M	-$15M	-$15M	-$15M	-$15M	-$15M	-$15M	-$15M	-$15M	-$15M	-$152M
DCF		-$14M	-$13M	-$11M	-$10M	-$9.4M	-$8.6M	-$7.8M	-$7.1M	-$6.5M	-$5.9M	-$59M
Value	-$152M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	2%	-27%	-115%	-100%	-74%
ROA	-	-7%	-32%	-28%	-25%
ROE	-	-7%	-48%	-41%	-36%

Bad Net Margins (-73.83%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-0.41	-0.4	-0.5	-0.96
Debt over Equity	0	0.08	0.22	0.15	0.17
Growth Stability	-	-	-	-	1

Good Debt/FCF ratio (-0.96)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (0.17)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	18%	12%	-11%	-2%
Earnings YoY growth	-	-2K%	384%	-23%	-
Equity YoY growth	-	754%	-30%	-10%	41%
FCF YoY growth	-	878%	92%	-52%	-